Role of Chemotherapy in Hodgkin's Lymphoma

被引：16

作者：

Seam, Pamela ^{[1
]}

Janik, John E. ^{[1
]}

Longo, Dan L. ^{[2
]}

DeVita, Vincent T., Jr. ^{[3
]}

机构：

[1] NCI, Clin Trials Team, Metab Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NIA, Clin Res Branch, NIH, Baltimore, MD 21224 USA

[3] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA

来源：

CANCER JOURNAL | 2009年 / 15卷 / 02期

基金：

美国国家卫生研究院;

关键词：

Hodgkin's lymphoma; antineoplastic agents; combined modality therapy; positron emission tomography; NATIONAL-CANCER-INSTITUTE; CLINICAL-TRIALS GROUP; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; INTERGROUP TRIAL; RANDOMIZED-TRIAL; MOPP/ABV HYBRID; STANFORD-V; ADJUVANT RADIOTHERAPY; PROGNOSTIC SCORE;

D O I：

10.1097/PPO.0b013e3181a27018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of curative chemotherapy regimens for the treatment of Hodgkin's lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.

引用

页码：150 / 154

页数：5

共 43 条

[1]

Abbondanzo Susan L, 2003, Ann Diagn Pathol, V7, P333, DOI 10.1016/S1092-9134(03)00077-7

[2] BRIEF CHEMOTHERAPY, STANFORD-V, AND ADJUVANT RADIOTHERAPY FOR BULKY OR ADVANCED-STAGE HODGKINS-DISEASE - A PRELIMINARY-REPORT [J].

BARTLETT, NL ;

ROSENBERG, SA ;

HOPPE, RT ;

HANCOCK, SL ;

HORNING, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1080-1088

[3] DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE [J].

BLAYNEY, DW ;

LONGO, DL ;

YOUNG, RC ;

GREENE, MH ;

HUBBARD, SM ;

POSTAL, MG ;

DUFFEY, PL ;

DEVITA, VT .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12) :710-714

[4] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].

BONADONNA, G ;

VALAGUSSA, P ;

SANTORO, A .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746

[5]

BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO

[6]

2-7

[7] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].

CANELLOS, GP ;

ANDERSON, JR ;

PROPERT, KJ ;

NISSEN, N ;

COOPER, MR ;

HENDERSON, ES ;

GREEN, MR ;

GOTTLIEB, A ;

PETERSON, BA .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484

[8]

CARBONE PP, 1971, CANCER RES, V31, P1860

[9] Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group [J].

Connors, JM ;

Klimo, P ;

Adams, G ;

Burns, BF ;

Cooper, I ;

Meyer, RM ;

OReilly, SE ;

Pater, J ;

Quirt, I ;

Sadura, A ;

Shustik, C ;

Skillings, J ;

Sutcliffe, S ;

Verma, S ;

Yoshida, S ;

Zee, B .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1638-1645

[10] Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome [J].

Dann, Eldad J. ;

Bar-Shalom, Rachel ;

Tamir, Ada ;

Haim, Nissim ;

Ben-Shachar, Menachem ;

Avivi, Irit ;

Zuckerman, Tzila ;

Kirschbaum, Mark ;

Goor, Odelia ;

Libster, Diana ;

Rowe, Jacob M. ;

Epelbaum, Ron .

BLOOD, 2007, 109 (03) :905-909

← 1 2 3 4 5 →